Hudson Bay Capital Management LP Lowers Holdings in Alnylam Pharmaceuticals, Inc. $ALNY

Hudson Bay Capital Management LP lowered its stake in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 38.7% in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 9,411 shares of the biopharmaceutical company’s stock after selling 5,937 shares during the quarter. Hudson Bay Capital Management LP’s holdings in Alnylam Pharmaceuticals were worth $4,291,000 at the end of the most recent quarter.

Other large investors have also modified their holdings of the company. Root Financial Partners LLC purchased a new stake in Alnylam Pharmaceuticals in the third quarter valued at approximately $25,000. Salomon & Ludwin LLC acquired a new position in Alnylam Pharmaceuticals during the third quarter worth approximately $27,000. Caitong International Asset Management Co. Ltd acquired a new position in Alnylam Pharmaceuticals during the third quarter worth approximately $29,000. Ameriflex Group Inc. purchased a new position in Alnylam Pharmaceuticals during the third quarter worth approximately $32,000. Finally, Aster Capital Management DIFC Ltd purchased a new position in Alnylam Pharmaceuticals during the third quarter worth approximately $36,000. 92.97% of the stock is currently owned by hedge funds and other institutional investors.

Alnylam Pharmaceuticals Stock Up 0.3%

Shares of NASDAQ ALNY opened at $312.17 on Friday. The stock has a fifty day moving average price of $335.41 and a 200 day moving average price of $405.07. The company has a current ratio of 2.76, a quick ratio of 2.71 and a debt-to-equity ratio of 1.28. Alnylam Pharmaceuticals, Inc. has a 12-month low of $205.87 and a 12-month high of $495.55. The company has a market cap of $41.40 billion, a P/E ratio of 182.56 and a beta of 0.36.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Thursday, February 12th. The biopharmaceutical company reported $1.25 earnings per share for the quarter, missing the consensus estimate of $1.43 by ($0.18). Alnylam Pharmaceuticals had a return on equity of 69.02% and a net margin of 6.43%.The company had revenue of $1.10 billion during the quarter, compared to analysts’ expectations of $1.16 billion. During the same period in the previous year, the company earned ($0.65) EPS. Alnylam Pharmaceuticals’s quarterly revenue was up 84.9% on a year-over-year basis. Research analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 EPS for the current fiscal year.

Analysts Set New Price Targets

Several analysts have recently issued reports on ALNY shares. Morgan Stanley lowered their price objective on shares of Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating for the company in a research note on Friday, January 30th. HC Wainwright reiterated a “buy” rating and issued a $510.00 target price on shares of Alnylam Pharmaceuticals in a report on Wednesday, February 18th. Raymond James Financial reissued an “outperform” rating and set a $472.00 price target on shares of Alnylam Pharmaceuticals in a research report on Monday, January 12th. Weiss Ratings upgraded Alnylam Pharmaceuticals from a “sell (d-)” rating to a “hold (c-)” rating in a report on Thursday, January 15th. Finally, Oppenheimer started coverage on Alnylam Pharmaceuticals in a research note on Wednesday, January 7th. They issued an “outperform” rating and a $500.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, twenty have given a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat, Alnylam Pharmaceuticals presently has an average rating of “Moderate Buy” and a consensus target price of $468.84.

Insider Buying and Selling

In other news, EVP Pushkal Garg sold 2,242 shares of Alnylam Pharmaceuticals stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $310.08, for a total transaction of $695,199.36. Following the sale, the executive vice president owned 24,848 shares in the company, valued at $7,704,867.84. This trade represents a 8.28% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 2,290 shares of the business’s stock in a transaction on Tuesday, January 13th. The stock was sold at an average price of $370.33, for a total transaction of $848,055.70. Following the transaction, the executive vice president directly owned 21,264 shares in the company, valued at approximately $7,874,697.12. The trade was a 9.72% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 53,923 shares of company stock valued at $18,072,087. Insiders own 1.50% of the company’s stock.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.